Trinity Biotech PLC (TRIB) stock
TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$6.24+0.75 (+13.76%)
Close on Nov 20, 2026Market cap $116.75MP/E –Yield –
Trinity Biotech gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2025 it was $16.89M, down 21.2% from the year before. Over ten years it grew -9.6% a year on average. The highest annual figure on record is $48.58M in fiscal 2020.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.89M | -21.2% |
| FY2024 | Dec 31, 2024 | $21.44M | +10.2% |
| FY2023 | Dec 31, 2023 | $19.45M | +12.6% |
| FY2022 | Dec 31, 2022 | $17.27M | -48.4% |
| FY2021 | Dec 31, 2021 | $33.45M | -31.1% |
| FY2020 | Dec 31, 2020 | $48.58M | +27.4% |
| FY2019 | Dec 31, 2019 | $38.12M | -8.0% |
| FY2018 | Dec 31, 2018 | $41.45M | -1.1% |
| FY2017 | Dec 31, 2017 | $41.89M | -3.7% |
| FY2016 | Dec 31, 2016 | $43.48M | -6.5% |
| FY2015 | Dec 31, 2015 | $46.51M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2018 | Jun 30, 2018 | $10.81M | – |
| Q2 FY2017 | Jun 30, 2017 | $10.82M | – |
See a number that looks wrong?